Aurinia Pharmaceuticals
- Company typePublic
- Founded2012
- HeadquartersVictoria, Canada
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Aurinia Pharmaceuticals firmographics
Firmographics- Name
- Aurinia Pharmaceuticals
- Legal name
- Aurinia Pharmaceuticals Inc.
- Website
- https://auriniapharma.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Aurinia Pharmaceuticals industry classification
Industry- Product category
- Lupus Nephritis Therapeutics
- NAICS
- Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where Aurinia Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Victoria
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
Aurinia Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- LUPKYNIS Product Sales: Aurinia generates primary revenue from net product sales of LUPKYNIS (voclosporin), its FDA-approved oral therapy for active lupus nephritis. Q1 2026 net product sales were $73.6 million, representing 23% year-over-year growth. Full-year 2025 net product sales reached $271.3 million, growing 25% compared to 2024. 2026 guidance projects $305-315 million in net product sales.
- License and Royalty Revenue (Otsuka Partnership): Aurinia receives license, royalty, and collaboration revenue from its partnership with Otsuka for LUPKYNIS commercialization in Japan. Otsuka filed a New Drug Application (NDA) for voclosporin in Japan, and the product received regulatory approval in Japan in September 2024. Aurinia also expanded internationally with approvals in the UK, EU (European Commission), and Switzerland.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | LUPKYNIS (voclosporin) 23.7 mg twice daily dosing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Aurinia Pharmaceuticals product offering
Product offeringCore offering
Aurinia Pharmaceuticals develops and commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral calcineurin inhibitor therapy for the treatment of adult patients with active lupus nephritis, generating net product sales of $271.3 million in 2025. The company also develops pipeline assets including aritinercept (AUR200), a dual BAFF/APRIL inhibitor, and zetomipzomib, a first-in-class immunoproteasome inhibitor acquired from Kezar Life Sciences in 2026, both targeting serious autoimmune diseases.
Product overview
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases. The company's commercial product portfolio centers on LUPKYNIS (voclosporin), the first FDA-approved oral therapy for active lupus nephritis, launched in January 2021. The pipeline includes aritinercept (AUR200), a dual BAFF/APRIL inhibitor in Phase 1 development for autoimmune diseases, and zetomipzomib, an immunoproteasome inhibitor acquired from Kezar Life Sciences in 2026 for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The company operates from corporate headquarters in Edmonton, Alberta and U.S. commercial offices in Rockville, Maryland.
Differentiator
Problem solved
Functional benefit
Brands
- LUPKYNIS: FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (voclosporin)
- Aritinercept
- Zetomipzomib
Products and services
- LUPKYNIS (voclosporin) LUPKYNIS is the first and only FDA-approved oral second-generation calcineurin inhibitor therapy for adult patients with active lupus nephritis. It has a dual mechanism of action: immunosuppression through inhibition of T-cell activation and cytokine production, combined with podocyte stability in the kidney. Recommended starting dose is three capsules twice daily with no requirement for serum drug monitoring.
- Aritinercept (AUR200) Aritinercept is a dual BAFF/APRIL inhibitor in clinical development for autoimmune diseases. It features a BCMA-engineered extracellular binding domain and IgG4 Fc domain, with binding affinities of 147 pM for BAFF and 28 pM for APRIL. Phase 1 study results support monthly dosing.
- Aurinia Alliance Aurinia Alliance is a patient support program providing resources, education, and assistance for patients prescribed LUPKYNIS, including access support, financial assistance, and ongoing patient education services.
Quantifiable outcome
- 53% reduction in risk of renal-related event or death (hazard ratio=0.47; p=0.0007) in AURORA 1 post-hoc analysis at EULAR 2026
- +3 more outcomes
Companies that use Aurinia Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Aurinia Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Aurinia Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- Enodia TherapeuticsminorKezar Life Sciences agreed to sell certain assets to Enodia Therapeutics as part of the restructuring prior to its acquisition by Aurinia. The transaction involved potential milestone payments related to zetomipzomib development.
- Alliance AdvisorsminorAlliance Advisors served as Information Agent for Kezar Life Sciences' tender offer, which was acquired by Aurinia Pharmaceuticals. This was noted as Alliance's 10th successful tender offer for pharmaceutical and biotechnology companies in the past 12 months.
- OtsukacoreOtsuka is a collaboration partner for the commercialization and development of LUPKYNIS (voclosporin) in Japan. Otsuka filed a New Drug Application (NDA) for voclosporin in Japan, and the product received regulatory approval from Japan's PMDA in September 2024. The partnership expands Aurinia's international footprint and provides royalty revenue stream from Japanese sales.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Aurinia Pharmaceuticals competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Aurinia Pharmaceuticals social profiles
Digital presenceAurinia Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aurinia Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
Aurinia Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Aurinia Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds8 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aurinia Pharmaceuticals M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aurinia Pharmaceuticals
What does Aurinia Pharmaceuticals do?
Aurinia Pharmaceuticals develops and commercializes LUPKYNIS (voclosporin), the first and only FDA-approved oral calcineurin inhibitor therapy for the treatment of adult patients with active lupus nephritis, generating net product sales of $271.3 million in 2025. The company also develops pipeline assets including aritinercept (AUR200), a dual BAFF/APRIL inhibitor, and zetomipzomib, a first-in-class immunoproteasome inhibitor acquired from Kezar Life Sciences in 2026, both targeting serious autoimmune diseases.
Is Aurinia Pharmaceuticals a public or private company?
Aurinia Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Aurinia Pharmaceuticals founded?
Aurinia Pharmaceuticals was founded in 2012. It employs 101 to 250 people.
Where is Aurinia Pharmaceuticals based?
Aurinia Pharmaceuticals is headquartered in Victoria, Canada, in the North America region.
How does Aurinia Pharmaceuticals make money?
Two revenue lines are on record. LUPKYNIS Product Sales are the primary driver. The others are license and Royalty Revenue (Otsuka Partnership).
Does Aurinia Pharmaceuticals have an API?
No public API is recorded for Aurinia Pharmaceuticals.
What industry is Aurinia Pharmaceuticals in?
Aurinia Pharmaceuticals's product category is Lupus Nephritis Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 5417 and its SIC code is 5122.